nodes	percent_of_prediction	percent_of_DWPC	metapath
Lubiprostone—CBR1—Doxorubicin—urinary bladder cancer	0.648	1	CbGbCtD
Lubiprostone—CLCN2—prostate gland—urinary bladder cancer	0.0202	0.154	CbGeAlD
Lubiprostone—CLCN2—seminal vesicle—urinary bladder cancer	0.0171	0.131	CbGeAlD
Lubiprostone—CLCN2—epithelium—urinary bladder cancer	0.0148	0.114	CbGeAlD
Lubiprostone—CLCN2—smooth muscle tissue—urinary bladder cancer	0.0143	0.109	CbGeAlD
Lubiprostone—CLCN2—female reproductive system—urinary bladder cancer	0.011	0.0843	CbGeAlD
Lubiprostone—CBR1—Synthesis of Prostaglandins (PG) and Thromboxanes (TX)—HPGDS—urinary bladder cancer	0.0106	0.161	CbGpPWpGaD
Lubiprostone—CLCN2—vagina—urinary bladder cancer	0.00996	0.0763	CbGeAlD
Lubiprostone—CBR1—prostate gland—urinary bladder cancer	0.00809	0.0619	CbGeAlD
Lubiprostone—CLCN2—Stimuli-sensing channels—TRPV1—urinary bladder cancer	0.00718	0.11	CbGpPWpGaD
Lubiprostone—CBR1—Arachidonic acid metabolism—CYP4B1—urinary bladder cancer	0.00718	0.11	CbGpPWpGaD
Lubiprostone—CBR1—seminal vesicle—urinary bladder cancer	0.00684	0.0524	CbGeAlD
Lubiprostone—CLCN2—lymph node—urinary bladder cancer	0.00644	0.0493	CbGeAlD
Lubiprostone—CBR1—renal system—urinary bladder cancer	0.00551	0.0422	CbGeAlD
Lubiprostone—CBR1—urethra—urinary bladder cancer	0.00541	0.0415	CbGeAlD
Lubiprostone—CLCN2—Ion channel transport—TRPV1—urinary bladder cancer	0.00469	0.0715	CbGpPWpGaD
Lubiprostone—Dinoprostone—HPGDS—urinary bladder cancer	0.00453	1	CrCbGaD
Lubiprostone—CBR1—female reproductive system—urinary bladder cancer	0.00441	0.0338	CbGeAlD
Lubiprostone—CBR1—Azacitidine—Gemcitabine—urinary bladder cancer	0.00414	1	CbGdCrCtD
Lubiprostone—CBR1—vagina—urinary bladder cancer	0.00399	0.0306	CbGeAlD
Lubiprostone—CBR1—Arachidonic acid metabolism—HPGDS—urinary bladder cancer	0.00382	0.0583	CbGpPWpGaD
Lubiprostone—CBR1—Synthesis of Prostaglandins (PG) and Thromboxanes (TX)—PTGS2—urinary bladder cancer	0.00368	0.0562	CbGpPWpGaD
Lubiprostone—CBR1—NRF2 pathway—UGT2B7—urinary bladder cancer	0.00338	0.0516	CbGpPWpGaD
Lubiprostone—CLCN2—Transmembrane transport of small molecules—SLC14A2—urinary bladder cancer	0.00277	0.0422	CbGpPWpGaD
Lubiprostone—CBR1—lymph node—urinary bladder cancer	0.00258	0.0198	CbGeAlD
Lubiprostone—CBR1—Arachidonic acid metabolism—GPX1—urinary bladder cancer	0.00226	0.0345	CbGpPWpGaD
Lubiprostone—CLCN2—Transmembrane transport of small molecules—AQP3—urinary bladder cancer	0.002	0.0305	CbGpPWpGaD
Lubiprostone—CLCN2—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	0.00163	0.0249	CbGpPWpGaD
Lubiprostone—CBR1—Arachidonic acid metabolism—PTGS2—urinary bladder cancer	0.00133	0.0203	CbGpPWpGaD
Lubiprostone—CBR1—NRF2 pathway—NQO1—urinary bladder cancer	0.00131	0.0199	CbGpPWpGaD
Lubiprostone—CLCN2—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	0.0011	0.0168	CbGpPWpGaD
Lubiprostone—CBR1—NRF2 pathway—GSTP1—urinary bladder cancer	0.00109	0.0166	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	0.00103	0.0157	CbGpPWpGaD
Lubiprostone—CBR1—NRF2 pathway—GSTM1—urinary bladder cancer	0.001	0.0153	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism—GSTZ1—urinary bladder cancer	0.000585	0.00893	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism—NAT1—urinary bladder cancer	0.000555	0.00847	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism—GSTO2—urinary bladder cancer	0.000555	0.00847	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	0.000546	0.00833	CbGpPWpGaD
Lubiprostone—CLCN2—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	0.000516	0.00787	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism—UGT2B7—urinary bladder cancer	0.000508	0.00775	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism—CYP4B1—urinary bladder cancer	0.000457	0.00697	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism—SLC19A1—urinary bladder cancer	0.000432	0.00659	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism—PRSS3—urinary bladder cancer	0.000421	0.00642	CbGpPWpGaD
Lubiprostone—Nervous system disorder—Gemcitabine—urinary bladder cancer	0.000381	0.00259	CcSEcCtD
Lubiprostone—Feeling abnormal—Thiotepa—urinary bladder cancer	0.00038	0.00259	CcSEcCtD
Lubiprostone—Myalgia—Cisplatin—urinary bladder cancer	0.000377	0.00257	CcSEcCtD
Lubiprostone—Gastrointestinal pain—Thiotepa—urinary bladder cancer	0.000377	0.00257	CcSEcCtD
Lubiprostone—Skin disorder—Gemcitabine—urinary bladder cancer	0.000377	0.00257	CcSEcCtD
Lubiprostone—Ill-defined disorder—Etoposide—urinary bladder cancer	0.000377	0.00256	CcSEcCtD
Lubiprostone—Anxiety—Cisplatin—urinary bladder cancer	0.000376	0.00256	CcSEcCtD
Lubiprostone—Hyperhidrosis—Gemcitabine—urinary bladder cancer	0.000375	0.00255	CcSEcCtD
Lubiprostone—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—urinary bladder cancer	0.000375	0.00255	CcSEcCtD
Lubiprostone—Nervous system disorder—Fluorouracil—urinary bladder cancer	0.000374	0.00255	CcSEcCtD
Lubiprostone—Discomfort—Cisplatin—urinary bladder cancer	0.000373	0.00254	CcSEcCtD
Lubiprostone—Tachycardia—Fluorouracil—urinary bladder cancer	0.000372	0.00253	CcSEcCtD
Lubiprostone—Anorexia—Gemcitabine—urinary bladder cancer	0.00037	0.00252	CcSEcCtD
Lubiprostone—Malaise—Etoposide—urinary bladder cancer	0.000366	0.00249	CcSEcCtD
Lubiprostone—Abdominal pain—Thiotepa—urinary bladder cancer	0.000365	0.00248	CcSEcCtD
Lubiprostone—Anorexia—Fluorouracil—urinary bladder cancer	0.000364	0.00248	CcSEcCtD
Lubiprostone—Oedema—Cisplatin—urinary bladder cancer	0.000362	0.00246	CcSEcCtD
Lubiprostone—Loss of consciousness—Etoposide—urinary bladder cancer	0.000357	0.00243	CcSEcCtD
Lubiprostone—Lethargy—Doxorubicin—urinary bladder cancer	0.000357	0.00243	CcSEcCtD
Lubiprostone—Nervous system disorder—Cisplatin—urinary bladder cancer	0.000355	0.00241	CcSEcCtD
Lubiprostone—Cough—Etoposide—urinary bladder cancer	0.000354	0.00241	CcSEcCtD
Lubiprostone—Musculoskeletal discomfort—Gemcitabine—urinary bladder cancer	0.000354	0.00241	CcSEcCtD
Lubiprostone—Tachycardia—Cisplatin—urinary bladder cancer	0.000353	0.0024	CcSEcCtD
Lubiprostone—Skin disorder—Cisplatin—urinary bladder cancer	0.000351	0.00239	CcSEcCtD
Lubiprostone—Hyperhidrosis—Cisplatin—urinary bladder cancer	0.00035	0.00238	CcSEcCtD
Lubiprostone—Musculoskeletal discomfort—Fluorouracil—urinary bladder cancer	0.000348	0.00237	CcSEcCtD
Lubiprostone—Dyspnoea—Gemcitabine—urinary bladder cancer	0.000346	0.00236	CcSEcCtD
Lubiprostone—Chest pain—Etoposide—urinary bladder cancer	0.000346	0.00235	CcSEcCtD
Lubiprostone—Anorexia—Cisplatin—urinary bladder cancer	0.000345	0.00235	CcSEcCtD
Lubiprostone—Unspecified disorder of skin and subcutaneous tissue—Etoposide—urinary bladder cancer	0.000343	0.00234	CcSEcCtD
Lubiprostone—Discomfort—Etoposide—urinary bladder cancer	0.000342	0.00232	CcSEcCtD
Lubiprostone—Aspartate aminotransferase increased—Epirubicin—urinary bladder cancer	0.00034	0.00232	CcSEcCtD
Lubiprostone—Dyspnoea—Fluorouracil—urinary bladder cancer	0.00034	0.00232	CcSEcCtD
Lubiprostone—Hypersensitivity—Thiotepa—urinary bladder cancer	0.00034	0.00231	CcSEcCtD
Lubiprostone—Decreased appetite—Gemcitabine—urinary bladder cancer	0.000337	0.0023	CcSEcCtD
Lubiprostone—CBR1—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	0.000337	0.00515	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism—TYMP—urinary bladder cancer	0.000336	0.00513	CbGpPWpGaD
Lubiprostone—Dyspepsia—Fluorouracil—urinary bladder cancer	0.000336	0.00229	CcSEcCtD
Lubiprostone—Gastrointestinal disorder—Gemcitabine—urinary bladder cancer	0.000335	0.00228	CcSEcCtD
Lubiprostone—Abdominal discomfort—Methotrexate—urinary bladder cancer	0.000335	0.00228	CcSEcCtD
Lubiprostone—Fatigue—Gemcitabine—urinary bladder cancer	0.000335	0.00228	CcSEcCtD
Lubiprostone—Gastritis—Epirubicin—urinary bladder cancer	0.000335	0.00228	CcSEcCtD
Lubiprostone—Alanine aminotransferase increased—Epirubicin—urinary bladder cancer	0.000333	0.00227	CcSEcCtD
Lubiprostone—Constipation—Gemcitabine—urinary bladder cancer	0.000332	0.00226	CcSEcCtD
Lubiprostone—Pain—Gemcitabine—urinary bladder cancer	0.000332	0.00226	CcSEcCtD
Lubiprostone—Decreased appetite—Fluorouracil—urinary bladder cancer	0.000332	0.00226	CcSEcCtD
Lubiprostone—Asthenia—Thiotepa—urinary bladder cancer	0.000331	0.00225	CcSEcCtD
Lubiprostone—Musculoskeletal discomfort—Cisplatin—urinary bladder cancer	0.00033	0.00224	CcSEcCtD
Lubiprostone—Gastrointestinal disorder—Fluorouracil—urinary bladder cancer	0.000329	0.00224	CcSEcCtD
Lubiprostone—Abdominal distension—Epirubicin—urinary bladder cancer	0.000329	0.00224	CcSEcCtD
Lubiprostone—Influenza—Epirubicin—urinary bladder cancer	0.000327	0.00222	CcSEcCtD
Lubiprostone—Pain—Fluorouracil—urinary bladder cancer	0.000326	0.00222	CcSEcCtD
Lubiprostone—Tachycardia—Etoposide—urinary bladder cancer	0.000323	0.0022	CcSEcCtD
Lubiprostone—CBR1—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	0.000323	0.00493	CbGpPWpGaD
Lubiprostone—Dyspnoea—Cisplatin—urinary bladder cancer	0.000323	0.0022	CcSEcCtD
Lubiprostone—Skin disorder—Etoposide—urinary bladder cancer	0.000322	0.00219	CcSEcCtD
Lubiprostone—Hyperhidrosis—Etoposide—urinary bladder cancer	0.00032	0.00218	CcSEcCtD
Lubiprostone—Feeling abnormal—Gemcitabine—urinary bladder cancer	0.00032	0.00218	CcSEcCtD
Lubiprostone—Anorexia—Etoposide—urinary bladder cancer	0.000316	0.00215	CcSEcCtD
Lubiprostone—Diarrhoea—Thiotepa—urinary bladder cancer	0.000316	0.00215	CcSEcCtD
Lubiprostone—Aspartate aminotransferase increased—Doxorubicin—urinary bladder cancer	0.000315	0.00214	CcSEcCtD
Lubiprostone—Decreased appetite—Cisplatin—urinary bladder cancer	0.000314	0.00214	CcSEcCtD
Lubiprostone—Feeling abnormal—Fluorouracil—urinary bladder cancer	0.000314	0.00214	CcSEcCtD
Lubiprostone—Gastrointestinal disorder—Cisplatin—urinary bladder cancer	0.000312	0.00213	CcSEcCtD
Lubiprostone—Gastritis—Doxorubicin—urinary bladder cancer	0.00031	0.00211	CcSEcCtD
Lubiprostone—Pain—Cisplatin—urinary bladder cancer	0.000309	0.00211	CcSEcCtD
Lubiprostone—Alanine aminotransferase increased—Doxorubicin—urinary bladder cancer	0.000308	0.0021	CcSEcCtD
Lubiprostone—Dizziness—Thiotepa—urinary bladder cancer	0.000305	0.00208	CcSEcCtD
Lubiprostone—Abdominal distension—Doxorubicin—urinary bladder cancer	0.000304	0.00207	CcSEcCtD
Lubiprostone—CBR1—Metabolism—NAT2—urinary bladder cancer	0.000304	0.00464	CbGpPWpGaD
Lubiprostone—Influenza—Doxorubicin—urinary bladder cancer	0.000302	0.00206	CcSEcCtD
Lubiprostone—Pollakiuria—Epirubicin—urinary bladder cancer	0.000302	0.00205	CcSEcCtD
Lubiprostone—Feeling abnormal—Cisplatin—urinary bladder cancer	0.000298	0.00203	CcSEcCtD
Lubiprostone—Weight increased—Epirubicin—urinary bladder cancer	0.000297	0.00202	CcSEcCtD
Lubiprostone—Dyspnoea—Etoposide—urinary bladder cancer	0.000295	0.00201	CcSEcCtD
Lubiprostone—Vomiting—Thiotepa—urinary bladder cancer	0.000293	0.002	CcSEcCtD
Lubiprostone—Rash—Thiotepa—urinary bladder cancer	0.000291	0.00198	CcSEcCtD
Lubiprostone—Dermatitis—Thiotepa—urinary bladder cancer	0.000291	0.00198	CcSEcCtD
Lubiprostone—Headache—Thiotepa—urinary bladder cancer	0.000289	0.00197	CcSEcCtD
Lubiprostone—Decreased appetite—Etoposide—urinary bladder cancer	0.000288	0.00196	CcSEcCtD
Lubiprostone—Gastrointestinal disorder—Etoposide—urinary bladder cancer	0.000286	0.00195	CcSEcCtD
Lubiprostone—Fatigue—Etoposide—urinary bladder cancer	0.000286	0.00194	CcSEcCtD
Lubiprostone—Pain—Etoposide—urinary bladder cancer	0.000283	0.00193	CcSEcCtD
Lubiprostone—Constipation—Etoposide—urinary bladder cancer	0.000283	0.00193	CcSEcCtD
Lubiprostone—Urinary tract infection—Epirubicin—urinary bladder cancer	0.000283	0.00193	CcSEcCtD
Lubiprostone—Hypersensitivity—Fluorouracil—urinary bladder cancer	0.000281	0.00191	CcSEcCtD
Lubiprostone—Pollakiuria—Doxorubicin—urinary bladder cancer	0.000279	0.0019	CcSEcCtD
Lubiprostone—Asthenia—Gemcitabine—urinary bladder cancer	0.000278	0.0019	CcSEcCtD
Lubiprostone—Weight increased—Doxorubicin—urinary bladder cancer	0.000275	0.00187	CcSEcCtD
Lubiprostone—Nausea—Thiotepa—urinary bladder cancer	0.000274	0.00187	CcSEcCtD
Lubiprostone—Feeling abnormal—Etoposide—urinary bladder cancer	0.000273	0.00186	CcSEcCtD
Lubiprostone—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.000271	0.00184	CcSEcCtD
Lubiprostone—Hypersensitivity—Cisplatin—urinary bladder cancer	0.000267	0.00181	CcSEcCtD
Lubiprostone—Diarrhoea—Gemcitabine—urinary bladder cancer	0.000266	0.00181	CcSEcCtD
Lubiprostone—CBR1—Metabolism—RRM2—urinary bladder cancer	0.000263	0.00401	CbGpPWpGaD
Lubiprostone—Abdominal pain—Etoposide—urinary bladder cancer	0.000262	0.00178	CcSEcCtD
Lubiprostone—Urinary tract infection—Doxorubicin—urinary bladder cancer	0.000262	0.00178	CcSEcCtD
Lubiprostone—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000261	0.00178	CcSEcCtD
Lubiprostone—Asthenia—Cisplatin—urinary bladder cancer	0.00026	0.00177	CcSEcCtD
Lubiprostone—Oedema peripheral—Epirubicin—urinary bladder cancer	0.000258	0.00175	CcSEcCtD
Lubiprostone—Connective tissue disorder—Epirubicin—urinary bladder cancer	0.000257	0.00175	CcSEcCtD
Lubiprostone—Dizziness—Fluorouracil—urinary bladder cancer	0.000252	0.00172	CcSEcCtD
Lubiprostone—Mediastinal disorder—Methotrexate—urinary bladder cancer	0.000252	0.00171	CcSEcCtD
Lubiprostone—Diarrhoea—Cisplatin—urinary bladder cancer	0.000248	0.00168	CcSEcCtD
Lubiprostone—Vomiting—Gemcitabine—urinary bladder cancer	0.000247	0.00168	CcSEcCtD
Lubiprostone—Mental disorder—Methotrexate—urinary bladder cancer	0.000245	0.00167	CcSEcCtD
Lubiprostone—Rash—Gemcitabine—urinary bladder cancer	0.000245	0.00167	CcSEcCtD
Lubiprostone—Dermatitis—Gemcitabine—urinary bladder cancer	0.000245	0.00166	CcSEcCtD
Lubiprostone—Hypersensitivity—Etoposide—urinary bladder cancer	0.000244	0.00166	CcSEcCtD
Lubiprostone—Malnutrition—Methotrexate—urinary bladder cancer	0.000243	0.00166	CcSEcCtD
Lubiprostone—Erythema—Methotrexate—urinary bladder cancer	0.000243	0.00166	CcSEcCtD
Lubiprostone—Headache—Gemcitabine—urinary bladder cancer	0.000243	0.00165	CcSEcCtD
Lubiprostone—CBR1—Metabolism—ENO2—urinary bladder cancer	0.000243	0.00371	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism—HPGDS—urinary bladder cancer	0.000243	0.00371	CbGpPWpGaD
Lubiprostone—Vomiting—Fluorouracil—urinary bladder cancer	0.000243	0.00165	CcSEcCtD
Lubiprostone—CBR1—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	0.000242	0.00369	CbGpPWpGaD
Lubiprostone—Rash—Fluorouracil—urinary bladder cancer	0.000241	0.00164	CcSEcCtD
Lubiprostone—Dermatitis—Fluorouracil—urinary bladder cancer	0.00024	0.00164	CcSEcCtD
Lubiprostone—Headache—Fluorouracil—urinary bladder cancer	0.000239	0.00163	CcSEcCtD
Lubiprostone—Oedema peripheral—Doxorubicin—urinary bladder cancer	0.000238	0.00162	CcSEcCtD
Lubiprostone—Dysgeusia—Methotrexate—urinary bladder cancer	0.000238	0.00162	CcSEcCtD
Lubiprostone—Asthenia—Etoposide—urinary bladder cancer	0.000238	0.00162	CcSEcCtD
Lubiprostone—Connective tissue disorder—Doxorubicin—urinary bladder cancer	0.000238	0.00162	CcSEcCtD
Lubiprostone—CBR1—Metabolism—GSTT1—urinary bladder cancer	0.000236	0.0036	CbGpPWpGaD
Lubiprostone—Mediastinal disorder—Epirubicin—urinary bladder cancer	0.000236	0.0016	CcSEcCtD
Lubiprostone—CBR1—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	0.000232	0.00354	CbGpPWpGaD
Lubiprostone—Nausea—Gemcitabine—urinary bladder cancer	0.000231	0.00157	CcSEcCtD
Lubiprostone—Vomiting—Cisplatin—urinary bladder cancer	0.00023	0.00157	CcSEcCtD
Lubiprostone—Mental disorder—Epirubicin—urinary bladder cancer	0.000229	0.00156	CcSEcCtD
Lubiprostone—Rash—Cisplatin—urinary bladder cancer	0.000228	0.00155	CcSEcCtD
Lubiprostone—Dermatitis—Cisplatin—urinary bladder cancer	0.000228	0.00155	CcSEcCtD
Lubiprostone—Erythema—Epirubicin—urinary bladder cancer	0.000228	0.00155	CcSEcCtD
Lubiprostone—Malnutrition—Epirubicin—urinary bladder cancer	0.000228	0.00155	CcSEcCtD
Lubiprostone—Diarrhoea—Etoposide—urinary bladder cancer	0.000227	0.00154	CcSEcCtD
Lubiprostone—Nausea—Fluorouracil—urinary bladder cancer	0.000227	0.00154	CcSEcCtD
Lubiprostone—Ill-defined disorder—Methotrexate—urinary bladder cancer	0.000226	0.00154	CcSEcCtD
Lubiprostone—Flatulence—Epirubicin—urinary bladder cancer	0.000224	0.00153	CcSEcCtD
Lubiprostone—Dysgeusia—Epirubicin—urinary bladder cancer	0.000223	0.00152	CcSEcCtD
Lubiprostone—Malaise—Methotrexate—urinary bladder cancer	0.000219	0.00149	CcSEcCtD
Lubiprostone—Dizziness—Etoposide—urinary bladder cancer	0.000219	0.00149	CcSEcCtD
Lubiprostone—Muscle spasms—Epirubicin—urinary bladder cancer	0.000219	0.00149	CcSEcCtD
Lubiprostone—Mediastinal disorder—Doxorubicin—urinary bladder cancer	0.000218	0.00148	CcSEcCtD
Lubiprostone—Nausea—Cisplatin—urinary bladder cancer	0.000215	0.00146	CcSEcCtD
Lubiprostone—Cough—Methotrexate—urinary bladder cancer	0.000212	0.00144	CcSEcCtD
Lubiprostone—Mental disorder—Doxorubicin—urinary bladder cancer	0.000212	0.00144	CcSEcCtD
Lubiprostone—Ill-defined disorder—Epirubicin—urinary bladder cancer	0.000211	0.00144	CcSEcCtD
Lubiprostone—Vomiting—Etoposide—urinary bladder cancer	0.000211	0.00143	CcSEcCtD
Lubiprostone—Erythema—Doxorubicin—urinary bladder cancer	0.000211	0.00143	CcSEcCtD
Lubiprostone—Malnutrition—Doxorubicin—urinary bladder cancer	0.000211	0.00143	CcSEcCtD
Lubiprostone—Rash—Etoposide—urinary bladder cancer	0.000209	0.00142	CcSEcCtD
Lubiprostone—Dermatitis—Etoposide—urinary bladder cancer	0.000209	0.00142	CcSEcCtD
Lubiprostone—Headache—Etoposide—urinary bladder cancer	0.000208	0.00141	CcSEcCtD
Lubiprostone—Flatulence—Doxorubicin—urinary bladder cancer	0.000208	0.00141	CcSEcCtD
Lubiprostone—Myalgia—Methotrexate—urinary bladder cancer	0.000207	0.00141	CcSEcCtD
Lubiprostone—Chest pain—Methotrexate—urinary bladder cancer	0.000207	0.00141	CcSEcCtD
Lubiprostone—Dysgeusia—Doxorubicin—urinary bladder cancer	0.000206	0.0014	CcSEcCtD
Lubiprostone—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	0.000206	0.0014	CcSEcCtD
Lubiprostone—Malaise—Epirubicin—urinary bladder cancer	0.000205	0.0014	CcSEcCtD
Lubiprostone—Discomfort—Methotrexate—urinary bladder cancer	0.000205	0.00139	CcSEcCtD
Lubiprostone—Syncope—Epirubicin—urinary bladder cancer	0.000204	0.00139	CcSEcCtD
Lubiprostone—Muscle spasms—Doxorubicin—urinary bladder cancer	0.000203	0.00138	CcSEcCtD
Lubiprostone—Palpitations—Epirubicin—urinary bladder cancer	0.000201	0.00137	CcSEcCtD
Lubiprostone—Loss of consciousness—Epirubicin—urinary bladder cancer	0.0002	0.00136	CcSEcCtD
Lubiprostone—Cough—Epirubicin—urinary bladder cancer	0.000199	0.00135	CcSEcCtD
Lubiprostone—Nausea—Etoposide—urinary bladder cancer	0.000197	0.00134	CcSEcCtD
Lubiprostone—CBR1—Metabolism—NQO1—urinary bladder cancer	0.000196	0.00299	CbGpPWpGaD
Lubiprostone—Ill-defined disorder—Doxorubicin—urinary bladder cancer	0.000195	0.00133	CcSEcCtD
Lubiprostone—Nervous system disorder—Methotrexate—urinary bladder cancer	0.000195	0.00133	CcSEcCtD
Lubiprostone—Myalgia—Epirubicin—urinary bladder cancer	0.000194	0.00132	CcSEcCtD
Lubiprostone—Chest pain—Epirubicin—urinary bladder cancer	0.000194	0.00132	CcSEcCtD
Lubiprostone—Anxiety—Epirubicin—urinary bladder cancer	0.000193	0.00131	CcSEcCtD
Lubiprostone—Skin disorder—Methotrexate—urinary bladder cancer	0.000193	0.00131	CcSEcCtD
Lubiprostone—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	0.000192	0.00131	CcSEcCtD
Lubiprostone—Hyperhidrosis—Methotrexate—urinary bladder cancer	0.000192	0.00131	CcSEcCtD
Lubiprostone—Discomfort—Epirubicin—urinary bladder cancer	0.000191	0.0013	CcSEcCtD
Lubiprostone—CBR1—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	0.00019	0.0029	CbGpPWpGaD
Lubiprostone—Malaise—Doxorubicin—urinary bladder cancer	0.00019	0.00129	CcSEcCtD
Lubiprostone—Dry mouth—Epirubicin—urinary bladder cancer	0.00019	0.00129	CcSEcCtD
Lubiprostone—Anorexia—Methotrexate—urinary bladder cancer	0.000189	0.00129	CcSEcCtD
Lubiprostone—Syncope—Doxorubicin—urinary bladder cancer	0.000189	0.00129	CcSEcCtD
Lubiprostone—Palpitations—Doxorubicin—urinary bladder cancer	0.000186	0.00127	CcSEcCtD
Lubiprostone—Oedema—Epirubicin—urinary bladder cancer	0.000186	0.00126	CcSEcCtD
Lubiprostone—Loss of consciousness—Doxorubicin—urinary bladder cancer	0.000185	0.00126	CcSEcCtD
Lubiprostone—Cough—Doxorubicin—urinary bladder cancer	0.000184	0.00125	CcSEcCtD
Lubiprostone—Shock—Epirubicin—urinary bladder cancer	0.000183	0.00124	CcSEcCtD
Lubiprostone—Nervous system disorder—Epirubicin—urinary bladder cancer	0.000182	0.00124	CcSEcCtD
Lubiprostone—Tachycardia—Epirubicin—urinary bladder cancer	0.000181	0.00123	CcSEcCtD
Lubiprostone—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	0.000181	0.00123	CcSEcCtD
Lubiprostone—Skin disorder—Epirubicin—urinary bladder cancer	0.00018	0.00123	CcSEcCtD
Lubiprostone—Hyperhidrosis—Epirubicin—urinary bladder cancer	0.00018	0.00122	CcSEcCtD
Lubiprostone—Chest pain—Doxorubicin—urinary bladder cancer	0.000179	0.00122	CcSEcCtD
Lubiprostone—Myalgia—Doxorubicin—urinary bladder cancer	0.000179	0.00122	CcSEcCtD
Lubiprostone—Anxiety—Doxorubicin—urinary bladder cancer	0.000179	0.00122	CcSEcCtD
Lubiprostone—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	0.000178	0.00121	CcSEcCtD
Lubiprostone—Discomfort—Doxorubicin—urinary bladder cancer	0.000177	0.00121	CcSEcCtD
Lubiprostone—Anorexia—Epirubicin—urinary bladder cancer	0.000177	0.00121	CcSEcCtD
Lubiprostone—Dyspnoea—Methotrexate—urinary bladder cancer	0.000177	0.0012	CcSEcCtD
Lubiprostone—Dry mouth—Doxorubicin—urinary bladder cancer	0.000175	0.00119	CcSEcCtD
Lubiprostone—Dyspepsia—Methotrexate—urinary bladder cancer	0.000175	0.00119	CcSEcCtD
Lubiprostone—Decreased appetite—Methotrexate—urinary bladder cancer	0.000173	0.00117	CcSEcCtD
Lubiprostone—Oedema—Doxorubicin—urinary bladder cancer	0.000172	0.00117	CcSEcCtD
Lubiprostone—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	0.000171	0.00117	CcSEcCtD
Lubiprostone—Fatigue—Methotrexate—urinary bladder cancer	0.000171	0.00116	CcSEcCtD
Lubiprostone—Pain—Methotrexate—urinary bladder cancer	0.00017	0.00116	CcSEcCtD
Lubiprostone—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	0.000169	0.00115	CcSEcCtD
Lubiprostone—Shock—Doxorubicin—urinary bladder cancer	0.000169	0.00115	CcSEcCtD
Lubiprostone—Nervous system disorder—Doxorubicin—urinary bladder cancer	0.000169	0.00115	CcSEcCtD
Lubiprostone—Tachycardia—Doxorubicin—urinary bladder cancer	0.000168	0.00114	CcSEcCtD
Lubiprostone—Skin disorder—Doxorubicin—urinary bladder cancer	0.000167	0.00114	CcSEcCtD
Lubiprostone—Hyperhidrosis—Doxorubicin—urinary bladder cancer	0.000166	0.00113	CcSEcCtD
Lubiprostone—CBR1—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	0.000166	0.00253	CbGpPWpGaD
Lubiprostone—Dyspnoea—Epirubicin—urinary bladder cancer	0.000166	0.00113	CcSEcCtD
Lubiprostone—Anorexia—Doxorubicin—urinary bladder cancer	0.000164	0.00112	CcSEcCtD
Lubiprostone—Feeling abnormal—Methotrexate—urinary bladder cancer	0.000164	0.00111	CcSEcCtD
Lubiprostone—Dyspepsia—Epirubicin—urinary bladder cancer	0.000164	0.00111	CcSEcCtD
Lubiprostone—CBR1—Metabolism—GSTP1—urinary bladder cancer	0.000163	0.00249	CbGpPWpGaD
Lubiprostone—Gastrointestinal pain—Methotrexate—urinary bladder cancer	0.000162	0.0011	CcSEcCtD
Lubiprostone—Decreased appetite—Epirubicin—urinary bladder cancer	0.000162	0.0011	CcSEcCtD
Lubiprostone—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	0.00016	0.00109	CcSEcCtD
Lubiprostone—Fatigue—Epirubicin—urinary bladder cancer	0.00016	0.00109	CcSEcCtD
Lubiprostone—Pain—Epirubicin—urinary bladder cancer	0.000159	0.00108	CcSEcCtD
Lubiprostone—Constipation—Epirubicin—urinary bladder cancer	0.000159	0.00108	CcSEcCtD
Lubiprostone—CBR1—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	0.000158	0.00241	CbGpPWpGaD
Lubiprostone—Abdominal pain—Methotrexate—urinary bladder cancer	0.000157	0.00107	CcSEcCtD
Lubiprostone—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	0.000157	0.00107	CcSEcCtD
Lubiprostone—Dyspnoea—Doxorubicin—urinary bladder cancer	0.000153	0.00104	CcSEcCtD
Lubiprostone—Feeling abnormal—Epirubicin—urinary bladder cancer	0.000153	0.00104	CcSEcCtD
Lubiprostone—CBR1—Metabolism—TYMS—urinary bladder cancer	0.000152	0.00232	CbGpPWpGaD
Lubiprostone—Gastrointestinal pain—Epirubicin—urinary bladder cancer	0.000152	0.00103	CcSEcCtD
Lubiprostone—Dyspepsia—Doxorubicin—urinary bladder cancer	0.000151	0.00103	CcSEcCtD
Lubiprostone—CBR1—Metabolism—NCOR1—urinary bladder cancer	0.00015	0.00229	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism—GSTM1—urinary bladder cancer	0.00015	0.00229	CbGpPWpGaD
Lubiprostone—Decreased appetite—Doxorubicin—urinary bladder cancer	0.000149	0.00102	CcSEcCtD
Lubiprostone—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	0.000148	0.00101	CcSEcCtD
Lubiprostone—Fatigue—Doxorubicin—urinary bladder cancer	0.000148	0.00101	CcSEcCtD
Lubiprostone—Constipation—Doxorubicin—urinary bladder cancer	0.000147	0.001	CcSEcCtD
Lubiprostone—Pain—Doxorubicin—urinary bladder cancer	0.000147	0.001	CcSEcCtD
Lubiprostone—Abdominal pain—Epirubicin—urinary bladder cancer	0.000147	0.001	CcSEcCtD
Lubiprostone—Hypersensitivity—Methotrexate—urinary bladder cancer	0.000146	0.000995	CcSEcCtD
Lubiprostone—CBR1—Metabolism—GPX1—urinary bladder cancer	0.000144	0.00219	CbGpPWpGaD
Lubiprostone—Asthenia—Methotrexate—urinary bladder cancer	0.000142	0.000969	CcSEcCtD
Lubiprostone—Feeling abnormal—Doxorubicin—urinary bladder cancer	0.000142	0.000964	CcSEcCtD
Lubiprostone—CBR1—Metabolism—ERCC2—urinary bladder cancer	0.000141	0.00215	CbGpPWpGaD
Lubiprostone—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	0.000141	0.000957	CcSEcCtD
Lubiprostone—Hypersensitivity—Epirubicin—urinary bladder cancer	0.000137	0.000932	CcSEcCtD
Lubiprostone—Abdominal pain—Doxorubicin—urinary bladder cancer	0.000136	0.000925	CcSEcCtD
Lubiprostone—Diarrhoea—Methotrexate—urinary bladder cancer	0.000136	0.000924	CcSEcCtD
Lubiprostone—Asthenia—Epirubicin—urinary bladder cancer	0.000133	0.000907	CcSEcCtD
Lubiprostone—CBR1—Metabolism—MTHFR—urinary bladder cancer	0.000133	0.00203	CbGpPWpGaD
Lubiprostone—Dizziness—Methotrexate—urinary bladder cancer	0.000131	0.000893	CcSEcCtD
Lubiprostone—Diarrhoea—Epirubicin—urinary bladder cancer	0.000127	0.000865	CcSEcCtD
Lubiprostone—Hypersensitivity—Doxorubicin—urinary bladder cancer	0.000127	0.000862	CcSEcCtD
Lubiprostone—Vomiting—Methotrexate—urinary bladder cancer	0.000126	0.000859	CcSEcCtD
Lubiprostone—Rash—Methotrexate—urinary bladder cancer	0.000125	0.000852	CcSEcCtD
Lubiprostone—Dermatitis—Methotrexate—urinary bladder cancer	0.000125	0.000851	CcSEcCtD
Lubiprostone—Headache—Methotrexate—urinary bladder cancer	0.000124	0.000846	CcSEcCtD
Lubiprostone—Asthenia—Doxorubicin—urinary bladder cancer	0.000123	0.000839	CcSEcCtD
Lubiprostone—Dizziness—Epirubicin—urinary bladder cancer	0.000123	0.000836	CcSEcCtD
Lubiprostone—Vomiting—Epirubicin—urinary bladder cancer	0.000118	0.000804	CcSEcCtD
Lubiprostone—Nausea—Methotrexate—urinary bladder cancer	0.000118	0.000803	CcSEcCtD
Lubiprostone—Diarrhoea—Doxorubicin—urinary bladder cancer	0.000118	0.0008	CcSEcCtD
Lubiprostone—Rash—Epirubicin—urinary bladder cancer	0.000117	0.000797	CcSEcCtD
Lubiprostone—Dermatitis—Epirubicin—urinary bladder cancer	0.000117	0.000797	CcSEcCtD
Lubiprostone—Headache—Epirubicin—urinary bladder cancer	0.000116	0.000792	CcSEcCtD
Lubiprostone—Dizziness—Doxorubicin—urinary bladder cancer	0.000114	0.000774	CcSEcCtD
Lubiprostone—Nausea—Epirubicin—urinary bladder cancer	0.00011	0.000751	CcSEcCtD
Lubiprostone—Vomiting—Doxorubicin—urinary bladder cancer	0.000109	0.000744	CcSEcCtD
Lubiprostone—Rash—Doxorubicin—urinary bladder cancer	0.000108	0.000738	CcSEcCtD
Lubiprostone—Dermatitis—Doxorubicin—urinary bladder cancer	0.000108	0.000737	CcSEcCtD
Lubiprostone—Headache—Doxorubicin—urinary bladder cancer	0.000108	0.000733	CcSEcCtD
Lubiprostone—CBR1—Metabolism—PPARG—urinary bladder cancer	0.000108	0.00164	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism—CREBBP—urinary bladder cancer	0.000103	0.00158	CbGpPWpGaD
Lubiprostone—Nausea—Doxorubicin—urinary bladder cancer	0.000102	0.000695	CcSEcCtD
Lubiprostone—CBR1—Metabolism—PTGS2—urinary bladder cancer	8.47e-05	0.00129	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism—PTEN—urinary bladder cancer	7.38e-05	0.00113	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism—EP300—urinary bladder cancer	7.04e-05	0.00107	CbGpPWpGaD
